Clinical features and management of liver cirrhosis comorbid with severe acute respiratory syndrome coronavirus 2 infection
- VernacularTitle:肝硬化合并新型冠状病毒感染的临床特征和管理
- Author:
Wenli JIANG
1
;
Wenlong YANG
1
;
Lei LUO
1
Author Information
- Publication Type:Review
- Keywords: Liver Cirrhosis; COVID-19; COVID-19 Vaccines; Clinical Governance
- From: Journal of Clinical Hepatology 2026;42(1):203-208
- CountryChina
- Language:Chinese
- Abstract: Patients with liver cirrhosis are more susceptible to various bacterial or viral infections due to immune dysfunction. Recent studies have shown that compared with the general population， individuals with liver cirrhosis show a significant increase in the incidence rate of adverse outcomes after severe acute respiratory syndrome coronavirus 2 infection， including the progression of liver injury and the increase in mortality rate. Vaccination can reduce the incidence rates of breakthrough infections and severe coronavirus disease 2019 （COVID-19） in patients with liver cirrhosis， but such patients have low immune response and thus require booster doses to enhance immunity. This article reviews the clinical features of cirrhotic patients with COVID-19 and related management strategies， in order to provide evidence-based guidance for the clinical diagnosis and treatment of such patients.
